Drug Trial Radar · NCT07596784
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Aug 24, 2027
Study completion Aug 24, 2027
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
Conditions
- Generalized Myasthenia Gravis
- gMG
Interventions
RavulizumabDrug
Participants will receive ravulizumab via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score at Week 26Time frame: Baseline, Week 26
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China · Recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Fuzhou, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Shijiazhuang, China · Recruiting
Research Site
Taiyuan, China · Recruiting
Research Site
Tianjin, China · Recruiting
Research Site
Wuhan, China · Not yet recruiting
Research Site
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.